PFIZER INC

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 78003

CEO Pay Ratio

277:1

A. Bourla

CEO Total Comp

$27.6M

A. Bourla

Median Employee

$99,631

Revenue

$62.6B

FY 2025

Net Income

$7.8B

FY 2025

Free Cash Flow

$9.1B

FY 2025

Net Margin

12.4%

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

0.35%

For every $1,000 of profit, $3.55 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$62.6B	$63.6B	$58.5B	$100.3B	$81.3B
Gross Profit	—	—	—	—	—	—
Operating Income	—	—	—	—	—	—
Net Income	$7.8B	$8.0B	$2.1B	$31.4B	$22.0B
Operating CF	$11.7B	$12.7B	$8.7B	$29.3B	$32.6B
Capex	$2.6B	$2.9B	$3.9B	$3.2B	$2.7B
Free Cash Flow	$9.1B	$9.8B	$4.8B	$26.0B	$29.9B
Buybacks	—	$0	$0	$2.0B	$0
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—
Net Margin	12.4%	12.6%	3.6%	31.3%	27.0%
FCF Margin	14.5%	15.5%	8.2%	25.9%	36.7%
R&D / Revenue	—	—	—	—	—	—
Effective Tax	-3.5%	-0.3%	-105.4%	9.6%	7.6%
Debt / Equity	0.71	0.65	0.69	0.34	0.47
Buybacks / FCF	—	0.0%	0.0%	7.7%	0.0%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
A. BourlaChairman and Chief Executive Officer	$1.8M	$9.4M	$9.0M	$5.4M	$1.9M	$27.6M
C. BoshoffChief Scientific Officer and President, Research & Development	$1.4M	$1.8M	$3.0M	$3.1M	$648.0K	$10.0M
D. DentonChief Financial Officer, EVP	$1.4M	$2.4M	$2.5M	$2.8M	$613.8K	$9.7M
A. MalikChief U.S. Commercial Officer, EVP	$1.4M	$2.3M	$2.2M	$2.9M	$611.2K	$9.4M
D. LanklerChief Legal Officer, EVP	$1.4M	$2.0M	$2.2M	$2.7M	$793.6K	$9.1M